by Brian Shilhavy
Health Impact News
Reports on the dangers of the popular “anti-viral” flu drug Tamiflu (oseltamivir) have existed for over a decade now. One of the known side effects of this drug among children is that it causes hallucinations, and what some say resemble demonic attacks.
Tamiflu is also linked to increased suicides.
And yet, not only is this drug still on the market, it is still recommended for babies, children, and pregnant women by the CDC, even under HHS Secretary Kennedy’s leadership.
Many doctors have stopped prescribing it to children who are healthy as a prevention for influenza, but the official medical dogma has been that Tamiflu is still recommended in critically ill patients.
However, a new study has been published that blows that theory out of the water, showing how critically ill patients receive no health benefits from the drug, and that Tamiflu actually leads to increased rates of death.
I have been warning the public about the dangers of Tamiflu for almost a decade now. Here are some of our previous articles on Tamiflu:
The side effects of Tamiflu were so common in the past, that the horror stories of what children suffered routinely made it into the corporate media at local affiliates.
I have created a compilation of many of those reports, and all of these reports that made it into the corporate media are at least 6-8 years old now. The video is 10 minutes long. (You can also watch it here.)
Even the normally pro-pharma Wikipedia admits that there are problems with this dangerous drug.
Oseltamivir, sold under the brand name Tamiflu among others, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection.
They recommend it to prevent infection in those at high risk, but not the general population.
The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection.
Recommendations regarding oseltamivir are controversial as are criticisms of the recommendations. A 2014 Cochrane Review concluded that oseltamivir does not reduce hospitalizations, and that there is no evidence of reduction in complications of influenza. Two meta-analyses have concluded that benefits in those who are otherwise healthy do not outweigh its risks. They also found little evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations. (Source.)
However, now there is abundant evidence that Tamiflu is not effective for those “at high risk” either, and that it can actually hasten their death.
This is a “preprint” of the study published in The Lancet.
Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial
Abstract
Background: The antiviral oseltamivir is widely used for the treatment of critically ill patients with influenza. Evidence from randomised trials about its efficacy in the critically ill is lacking.
Methods: In an ongoing international, multifactorial, Bayesian adaptive platform randomised trial, we evaluated oseltamivir for 5 days, oseltamivir for 10 days, or no antiviral treatment in critically ill patients aged 12 years and older with confirmed influenza severe respiratory infection. The primary outcome was 90-day mortality. An odds ratio less than 1 indicates benefit from oseltamivir.
Findings: Between March 1, 2020 and March 13, 2026, 442 participants were randomised to receive 5 days of oseltamivir (n=162), 10 days of oseltamivir (n=156), or no antiviral (n=124). At a scheduled adaptive analysis, both oseltamivir durations met a predefined inferiority threshold (<0·2% probability of being the best treatment in the influenza antiviral domain), triggering cessation of recruitment. By day 90, 17 (13·7%) in the no antiviral group, 32 (19·8%) in the 5-day oseltamivir group, and 30 (19·4%) in the 10-day oseltamivir group had died. The median adjusted OR for 90-day mortality was 2·13 (95% CrI 1·03 to 4·52) for 5 days of oseltamivir and 2·17 (95% CrI 1·05 to 4·64) for 10 days of oseltamivir, favouring no antiviral. For the 5- and 10-day oseltamivir treatments, the posterior probabilities for harm, an adjusted OR >1, were 98·0% and 98·2%, respectively.
Interpretation: Treatment with oseltamivir is ineffective and highly likely to increase 90-day mortality in critically ill patients with influenza. (Source.)
Here is an editorial of this study that was just published in the New England Journal of Medicine Voices.
Oseltamivir Flops in the Critically Ill
Excerpts:
With only a few months to go before flu season kicks in, along comes a study that promises to upend clinical practice and guideline writers everywhere: the REMAP-CAP study, a randomized trial of 442 critically ill people with laboratory-confirmed influenza, comparing 5 days of oseltamivir, 10 days of oseltamivir, or no antiviral treatment.
Not only was oseltamivir ineffective, but there was a good chance it may even have made outcomes worse.
And even though we’re just seeing the study in preprint right now, there’s every reason to take the results seriously….
Read the full article here.
The “Demon Drug” Tamiflu is still recommended by the CDC for Babies, Children, and Pregnant Women
MAHA!
This article was written by Human Superior Intelligence (HSI)
See Also:
Understand the Times We are Currently Living Through
The post Why is this Deadly Flu Drug Still on the Market? “Demon Drug” Tamiflu Still being Prescribed to Infants, Children, and Pregnant Women first appeared on Health Impact News.
Login
